Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Injections, Subcutaneous × 30 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07603479 2026-05-22

A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Jecho Biopharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
14 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡